CMS Defends “Functional Equivalence”; AWP Proposal Ready, Scully Says
Executive Summary
The Centers for Medicare & Medicaid Services is sticking to its position that deeming Amgen's Aranesp "functionally equivalent" to Johnson & Johnson's Procrit is the best approach to handling the product under the Hospital Outpatient Prospective Payment System
You may also be interested in...
AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says
AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says
CMS “Functional Equivalence” Standard Targeted In Medicare Bills
CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill